Søgeord (prep) valgt.
6 emner vises.
1
U.S. Preparedness and Response to Increasing Clade I Mpox Cases in the Democratic Republic of the Congo - United States, 2024
Morbidity and Mortality Weekly Report (MMWR), 16.05.2024
Tilføjet 16.05.2024
This report describes the investigation of cases in the Democratic Republic of the Congo (DRC), CDC\'s support to DRC, and U.S. public health preparedness activities to date.
Læs mere
2
Anorectal lymphogranuloma venereum among men who have sex with men: a 3-year nationwide survey, France, 2020 to 2022
Olivia Peuchant, Cécile Laurier-Nadalié, Laura Albucher, Carla Balcon, Amandine Dolzy, Nadège Hénin, Arabella Touati, Cécile Bébéar and on behalf of the Anachla study group
Eurosurveillance latest updates, 10.05.2024
Tilføjet 10.05.2024
BackgroundIn France, lymphogranuloma venereum (LGV) testing switched from universal to selective testing in 2016. AimTo investigate changes in LGV-affected populations, we performed a nationwide survey based on temporarily reinstated universal LGV testing from 2020 to 2022. MethodsEach year, during three consecutive months, laboratories voluntarily sent anorectal Chlamydia trachomatis-positive samples from men and women to the National Reference Centre for bacterial sexually transmitted infections. We collected patients’ demographic, clinical and biological data. Genovars L of C. trachomatis were detected using real-time PCR. In LGV-positive samples, the ompA gene was sequenced. ResultsIn 2020, LGV positivity was 12.7% (146/1,147), 15.2% (138/907) in 2021 and 13.3% (151/1,137) in 2022 (p > 0.05). It occurred predominantly in men who have sex with men (MSM), with rare cases among transgender women. The proportion of HIV-negative individuals was higher than that of those living with HIV. Asymptomatic rectal LGV increased from 36.1% (44/122) in 2020 to 52.4% (66/126) in 2022 (p = 0.03). Among users of pre-exposure prophylaxis (PrEP), LGV positivity was 13.8% (49/354) in 2020, 15.6% (38/244) in 2021 and 10.9% (36/331) in 2022, and up to 50% reported no anorectal symptoms. Diversity of the LGV ompA genotypes in the Paris region increased during the survey period. An unexpectedly high number of ompA genotype L1 variant was reported in 2022. ConclusionIn rectal samples from MSM in France, LGV positivity was stable, but the proportion of asymptomatic cases increased in 2022. This underscores the need of universal LGV testing and the importance of continuous surveillance.
Læs mere
3
Contact tracing management of a measles case in a paediatric hospital: experience of the local public health unit, Portugal, January 2024
Daniel Saldanha Resendes, António Tomás, Mariana Pinção Cardoso, Sebastian von Schreeb, Rita Miranda Ferrão, Paula Vasconcelos, Maria Helena Almeida, Bruno Novo Castro, Vasco Ricoca Peixoto, Renato Lourenço Silva and Margarida de Morais
Eurosurveillance latest updates, 26.04.2024
Tilføjet 26.04.2024
In January 2024, a child was diagnosed with measles in a paediatric hospital in Lisbon. Of 123 contacts, 39 (32%) were not fully immunised, presenting a risk for a potential outbreak. The public health unit initiated control measures and identified challenges during the response, such as the lack of interoperability between information systems and accessing vaccination records. The lessons learned prompted changes to national contact tracing procedures for measles, further strengthening Portugal’s preparedness.
Læs mere
4
Questioning risk compensation: pre-exposure prophylaxis (PrEP) and sexually transmitted infections among men who have sex with men, capital region of Denmark, 2019 to 2022
Sebastian von Schreeb, Susanne Kriegel Pedersen, Hanne Christensen, Kristina Melbardis Jørgsensen, Lene Holm Harritshøj, Frederik Boetius Hertz, Magnus Glindvad Ahlström, Anne-Mette Lebech, Suzanne Lunding, Lars Nørregaard Nielsen, Jan Gerstoft, Gitte Kronborg and Frederik N Engsig
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundPre-exposure prophylaxis (PrEP) effectively prevents HIV, but its association with sexually transmitted infections (STIs) has raised concerns about risk compensation, potentially impacting the expansion of PrEP programmes. AimWe examined the relationship between PrEP and the incidence of chlamydia, gonorrhoea and syphilis. MethodsIn this prospective cohort study, we compared STI rates before and after PrEP initiation among users in the capital region of Denmark (2019–2022), calculating incidence rate ratios adjusted for age and testing frequency (aIRR). To pinpoint when increases began, we plotted weekly STI rates, adjusting the timeline to correspond with PrEP initiation. ResultsThe study included 1,326 PrEP users with a median age of 35 years. The STI incidence rate per 100,000 person-years rose from 35.3 before to 81.2 after PrEP start, with an aIRR of 1.35 (95% CI: 1.18–1.56). Notably, this increase preceded PrEP initiation by 10–20 weeks. Specific aIRR for chlamydia, gonorrhoea and syphilis were 1.23 (95% CI: 1.03–1.48), 1.24 (95% CI: 1.04–1.47) and 1.15 (95% CI: 0.76–1.72), respectively. In subanalyses for anatomical sites aIRR was 1.26 (95% CI: 1.01–1.56) for rectal chlamydia and 0.66 (95% CI: 0.45–0.96) for genital gonorrhoea. ConclusionWe found a 35% increase in STI incidence associated with PrEP use. It started before PrEP initiation, challenging the assumption that PrEP leads to risk compensation. Instead, the data suggest that individuals seek PrEP during periods of heightened sexual risk-taking. Consequently, PrEP programmes should include sexual health consultations, STI testing, treatment and prevention strategies to prevent HIV and improve sexual health.
Læs mere
5
Public health and social measures for health emergencies and pandemics in the EU/EEA: recommendations for strengthening preparedness planning
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This guidance outlines key strategic and operational considerations to inform pandemic preparedness planning round the design and implementation of public health and social measures in community settings in the EU/EEA.
Læs mere
6
AstraZeneca to Invest 650 Million Pounds in UK to Boost Pandemic Preparedness
Medscape Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on... Reuters Health Information
Læs mere